

# Evaluation and Treatment of Infertility

TAMMY J. LINDSAY, MD, *Saint Louis University Family Medicine Residency, Belleville, Illinois*

KIRSTEN R. VITRIKAS, MD, *David Grant Medical Center Family Medicine Residency, Travis Air Force Base, California*

Infertility is defined as the inability to achieve pregnancy after one year of regular, unprotected intercourse. Evaluation may be initiated sooner in patients who have risk factors for infertility or if the female partner is older than 35 years. Causes of infertility include male factors, ovulatory dysfunction, uterine abnormalities, tubal obstruction, peritoneal factors, or cervical factors. A history and physical examination can help direct the evaluation. Men should undergo evaluation with a semen analysis. Abnormalities of sperm may be treated with gonadotropin therapy, intrauterine insemination, or in vitro fertilization. Ovulation should be documented by serum progesterone level measurement at cycle day 21. Evaluation of the uterus and fallopian tubes can be performed by hysterosalpingography in women with no risk of obstruction. For patients with a history of endometriosis, pelvic infections, or ectopic pregnancy, evaluation with hysteroscopy or laparoscopy is recommended. Women with anovulation may be treated in the primary care setting with clomiphene to induce ovulation. Treatment of tubal obstruction generally requires referral for subspecialty care. Unexplained infertility in women or men may be managed with another year of unprotected intercourse, or may proceed to assisted reproductive technologies, such as intrauterine insemination or in vitro fertilization. (*Am Fam Physician*. 2015;91(5):308-314. Copyright © 2015 American Academy of Family Physicians.)

**CME** This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz Questions on page 284.

Author disclosure: No relevant financial affiliations.

Infertility is defined as the inability to become pregnant after 12 months of regular, unprotected intercourse. In a survey from 2006 to 2010, more than 1.5 million U.S. women, or 6% of the married population 15 to 44 years of age, reported infertility, and 6.7 million women reported impaired ability to get pregnant or carry a baby to term.<sup>1</sup> Among couples 15 to 44 years of age, nearly 7 million have used infertility services at some point.<sup>2</sup> This encompasses couples with infertility and impaired ability to get pregnant, but it does not capture those who are not married, so actual numbers may be underestimated. These numbers are comparable to those of other industrialized nations.<sup>3,4</sup> Infertility may arise from male factors, female factors, or a combination of these (*Table 1*<sup>5-8</sup>).

Because 85% of couples conceive spontaneously within 12 months if having intercourse regularly,<sup>5</sup> it is important to identify those who will benefit from infertility evaluation. Generally, evaluation should be offered to couples who have not conceived after one year of unprotected vaginal intercourse. Counseling about options should be offered to couples who are not physically able to conceive (i.e., same-sex couples or persons lacking reproductive organs). Women older than 35 years or couples with known risk

factors for infertility may warrant evaluation at six months.<sup>6,8</sup>

It is important for primary care physicians to be familiar with the workup and prognosis for infertile couples. A British study found that patients valued primary care physicians who were well informed about infertility and the treatment process.<sup>9</sup> Because anxiety over infertility may cause increased stress and decreased libido, further compounding the problem, formal counseling is encouraged for couples experiencing infertility.<sup>8</sup>

## Evaluation of Men

Causes of male infertility include infection, injury, toxin exposures, anatomic variances, chromosomal abnormalities, systemic diseases, and sperm antibodies. Additional risk factors may include smoking, alcohol use, obesity, and older age; however, the data are hampered by a lack of pregnancy-related outcomes.<sup>8-16</sup> One retrospective case-control study of 650 men with infertility and 698 control participants questioned the role of environmental risk; no association could be determined after assessing for multiple factors including shift work, stress, and pesticides.<sup>17</sup>

Evaluation of male infertility starts with a history and physical examination focusing on previous fertility, pelvic or inguinal

## SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
Confirmation of ovulation should be obtained with a serum progesterone level on day 21 of a 28-day cycle or one week before presumed onset of menses.	C	6, 8
Hysterosalpingography should be offered to screen for uterine and tubal abnormalities in women with infertility who have no history of pelvic infections, endometriosis, or ectopic pregnancy.	C	8, 26, 27
Women with unexplained infertility should not be offered ovulation induction or intrauterine insemination because these have not been shown to increase pregnancy rates.	C	8, 45
Women with a body mass index greater than 30 kg per m <sup>2</sup> should be counseled to lose weight because this may restore ovulation.	B	46

*A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.*

**Table 1. Etiology of Infertility**

<i>Factors</i>	<i>Percentage</i>
Combined factors	40
Male factors	26 to 30
Ovulatory dysfunction	21 to 25
Tubal factors	14 to 20
Other (e.g., cervical factors, peritoneal factors, uterine abnormalities)	10 to 13
Unexplained	25 to 28

*Information from references 5 through 8.*

surgeries, systemic diseases, and exposures. The laboratory evaluation begins with a semen analysis. Instructions for collecting the sample should include abstinence from ejaculation for 48 to 72 hours. Because sperm generation time is just over two months, it is recommended to wait three months before repeat sampling.<sup>8</sup> A normal sample according to the 2010 World Health Organization (WHO) guidelines is described in *Table 2*.<sup>18</sup> If the semen analysis result is abnormal, further evaluation is indicated (*Table 3*<sup>6-8,10,19,20</sup>). If oligospermia or azoospermia is noted, hypogonadism should be suspected. Obtaining morning levels of total testosterone (normal range = 240 to 950 ng per dL [8.3 to 33.0 nmol per L]) and follicle-stimulating hormone (FSH; normal range = 1.5 to 12.4 mIU per mL [1.5 to 12.4 IU per L]) can help differentiate between primary and secondary disorders. A decreased testosterone level with an increased FSH level points to primary hypogonadism. A low testosterone level with a low FSH level signals a secondary cause. Some causes, such as hyperprolactinemia, are reversible with proper treatment. Other testing may be needed based on circumstances, including testicular biopsy, genetic testing, and imaging (*Table 3*<sup>6-8,10,19,20</sup>). Postcoital testing and antisperm antibody testing are no longer considered useful in this evaluation.<sup>21,22</sup>

**Table 2. World Health Organization 2010 Semen Analysis Reference Guidelines**

<i>Characteristic</i>	<i>Normal reference</i>
Morphologically normal	4%
Motility (progressive)	32%
Motility (total)	40%
Sperm count	39 million per ejaculate; 15 million per mL
Vitality	58%
Volume	At least 1.5 mL

*NOTE: oligospermia = sperm count < 15 million per mL; asthenozoospermia = < 40% of the sperm are motile; teratozoospermia = normal morphology < 4%. If an individual has all three low sperm conditions, it is known as OAT syndrome, which is typically associated with an increased likelihood of genetic etiology of the infertility. Total motility differs from progressive motility only in the notation of forward movement.*

*Information from reference 18.*

## Evaluation of Women

The etiology of female infertility can be broken down into ovulation disorders, uterine abnormalities, tubal obstruction, and peritoneal factors. Cervical factors are also thought to play a minor role, although they are rarely the sole cause. Evaluation of cervical mucus is unreliable; therefore, investigation is not helpful with the management of infertility.<sup>6</sup>

The initial history should cover menstrual history, timing and frequency of intercourse, previous use of contraception, previous pregnancies and outcomes, pelvic infections, medication use, occupational exposures, substance abuse, alcohol intake, tobacco use, and previous surgery on reproductive organs. A review of systems and physical examination of the endocrine and gynecologic systems should be performed. Other considerations include preconception screening and vaccination for preventable diseases such as rubella and varicella,

**Table 3. Etiology and Evaluation of Infertility**

<i>Condition</i>	<i>History and physical examination</i>	<i>Laboratory and radiologic testing</i>
<b>Female</b>		
Endometriosis or pelvic adhesions	History of abdominal or pelvic surgery; history consistent with endometriosis	Rarely helpful
Hypothalamic amenorrhea	Amenorrhea or oligomenorrhea; low body mass index	Low to normal FSH level; low estradiol level
Ovarian failure/insufficiency	Amenorrhea or oligomenorrhea; menopausal symptoms; family history of early menopause; single ovary; chemotherapy or radiation therapy; previous ovarian surgery; history of autoimmune disease	Elevated FSH level; low estradiol level
Ovulatory disorder	Irregular menses; hirsutism; obesity (polycystic ovary syndrome); galactorrhea (hyperprolactinemia); fatigue; hair loss (hypothyroidism)	Progesterone level < 5 ng per mL (15.9 nmol per L); elevated prolactin level; low TSH level
Tubal blockage	History of pelvic infections or endometriosis	Abnormal hysterosalpingography result
Uterine abnormalities	Dyspareunia; dysmenorrhea; history of anatomic developmental abnormalities; family history of uterine fibroids; abnormal palpation and inspection	Abnormal hysterosalpingography or ultrasonography result
<b>Male</b>		
Genetic etiology: Y deletions XXY (Klinefelter syndrome)	Y deletions: small testes Klinefelter phenotype: small testes, tall, gynecomastia, learning disabilities	Both syndromes result in normal semen volume but low sperm count Y deletions may present as normal hormone levels or have an elevated FSH level Klinefelter syndrome typically results in low testosterone level and an elevated FSH level
Other genetics: CFTR gene (cystic fibrosis) 5T allele (cystic fibrosis)	Absence of the vas deferens	Low volume semen analysis
Obstruction of the vas deferens or epididymis Ejaculatory dysfunction	History of infection, trauma, or vasectomy; normal testicular examination	Low volume semen analysis; transrectal ultrasonography can identify obstruction
Systemic disease (not all-inclusive): Hemochromatosis Kallmann syndrome Pituitary tumor Sarcoidosis	—	Low FSH level; low testosterone level; check prolactin level and, if elevated, perform imaging for pituitary tumor
Unclear etiology	Normal testicular examination	Normal FSH level; normal semen volume; low sperm count

FSH = follicle-stimulating hormone; TSH = thyroid-stimulating hormone.

Information from references 6 through 8, 10, 19, and 20.

sexually transmitted infections, and cervical cancer, based on appropriate guidelines and risk.

WHO categorizes ovulatory disorders into three groups: group I is caused by hypothalamic pituitary failure (10%), group II results from dysfunction of hypothalamic-pituitary-ovarian axis (85%), and group III is caused by ovarian failure (5%).<sup>8</sup> Women in group I typically present with amenorrhea and low gonadotropin levels, most commonly from low body weight or

excessive exercise. Women in group II include those with polycystic ovary syndrome and hyperprolactinemia. Women in group III can conceive only with oocyte donation and in vitro fertilization.

Women with regular menstrual cycles are likely to be ovulating and should be offered serum progesterone testing at day 21 to confirm ovulation.<sup>8</sup> If a woman has irregular cycles, the testing should be conducted later in the cycle, starting seven days before presumed onset of

Comments

Generally diagnosed on laparoscopy; consider in women with otherwise unexplained infertility

Encourage weight gain

Consider additional tests of ovarian reserve (antral follicle count, antimüllerian hormone level, clomiphene [Clomid] challenge test)

Check TSH and prolactin levels based on clinical symptoms

Usually necessitates subspecialist referral for treatment

May necessitate subspecialist referral for treatment

Y deletions can be passed to offspring if intracytoplasmic sperm injection is used with in vitro fertilization; genetic counseling is indicated

Because of the inheritance pattern, genetic testing of the partner is warranted, and counseling is indicated if she is a carrier

Rare cause of infertility; evaluation reserved for fertility specialist

Infiltrative processes that cause a small number of infertility cases; however, effective treatment is available

Subspecialist may consider testicular biopsy to determine obstructive vs. nonobstructive azoospermia

menses, and repeated weekly until menses.<sup>6,8</sup> A progesterone level of 5 ng per mL (15.9 nmol per L) or greater implies ovulation.<sup>6,23</sup> Anovulatory women should have further investigation to determine treatable causes such as thyroid disorders or hyperprolactinemia based on symptoms.<sup>8</sup> A high serum FSH level (greater than 30 to 40 mIU per mL [30 to 40 IU per L]) with a low estradiol level can distinguish ovarian failure from hypothalamic pituitary failure, which typically reveals a low or normal

FSH level (less than 10 mIU per mL [10 IU per L]) and a low estradiol level. Basal body temperatures are no longer considered a reliable indicator of ovulation, and are not recommended for evaluating ovulation.<sup>6,8,23</sup>

A high FSH level (10 to 20 mIU per mL [10 to 20 IU per L]) drawn on day 3 of the menstrual cycle is associated with infertility. A high serum estradiol level (greater than 60 to 80 pg per mL [220 to 294 pmol per L]) in conjunction with a normal FSH level has also been associated with lower pregnancy rates. This combination of laboratory test results may indicate ovarian insufficiency or diminished ovarian reserve.<sup>24</sup> Other tests of ovarian reserve, such as the clomiphene (Clomid) challenge test, antral follicle count, and antimüllerian hormone level, are also generally performed to predict response to ovarian stimulation with exogenous gonadotropins and assisted reproductive technology. However, these tests have only poor to moderate predictive value despite widespread use.<sup>25</sup>

Women with no clear risk of tubal obstruction should be offered hysterosalpingography to screen for tubal occlusion and structural uterine abnormalities.<sup>8,26,27</sup> As opposed to laparoscopy or hysteroscopy, hysterosalpingography is a minimally invasive procedure with potentially therapeutic effects and should be considered before more invasive methods of assessing tubal patency.<sup>6</sup> Women with risk factors for tubal obstruction, such as endometriosis, previous pelvic infections, or ectopic pregnancy, should instead be offered hysteroscopy or laparoscopy with dye to assess for other pelvic pathology.<sup>8</sup> These studies are more sensitive and may delineate an abnormally formed uterus or structural problems, such as fibroids. This allows for the diagnosis and treatment of conditions such as endometriosis with one procedure. Treatment of tubal obstruction generally requires referral for subspecialty care.

Endometrial biopsy should be performed only in women with suspected pathology (chronic endometritis or neoplasia). Histologic endometrial dating is not considered reliable nor is it predictive of fertility.<sup>6,28</sup> Additionally, postcoital testing of cervical mucus is no longer recommended because it does not affect clinical management or predict the inability to conceive.<sup>22</sup>

**Treatment of Male Infertility**

Underlying etiology determines the therapeutic course, although male infertility is unexplained in 40% to 50% of cases.<sup>29</sup> When the semen analysis is abnormal, referral to a male fertility specialist or reproductive endocrinologist is warranted. When anatomic variance or obstruction is suspected, referral for surgical evaluation and treatment is appropriate. If an endocrinopathy, such as

## Infertility

hyperprolactinemia, is diagnosed, the underlying cause should be treated. In patients with varicocele, there is insufficient evidence to suggest corrective surgery will increase live birth rates, despite improvement in semen analysis results.<sup>30-32</sup> Other treatment options include antiestrogens and gonadotropin therapy, which showed a trend toward increased live birth rates in a Cochrane review.<sup>33</sup> Use of antioxidants such as zinc, vitamin E, or L-carnitine showed increased live birth rates in three small randomized controlled trials in couples undergoing assisted reproductive technology.<sup>34</sup> Although intrauterine insemination has been shown to be equally effective as timed intercourse in unstimulated cycles, there is a modest increase in live birth rates when combined with ovarian stimulation.<sup>8,33,35,36</sup> Lastly, in vitro fertilization, with or without intracytoplasmic sperm injection, is the mainstay of assisted reproductive technology for male factor infertility.

### Treatment of Anovulatory Conditions

Women with WHO group I ovulatory disorders should be counseled to achieve a normal body weight. They may benefit from referral to a physician comfortable with prescribing pulsatile administration of gonadotropin-releasing hormone or gonadotropins with luteinizing hormone activity to induce ovulation.<sup>8,37</sup>

Women in WHO group II, including those who are overweight and who have polycystic ovary syndrome, can benefit from weight loss, exercise, and lifestyle modifications to restore ovulatory cycles and achieve pregnancy.<sup>37</sup> Clomiphene has also proven effective for ovulation induction in women with polycystic ovary syndrome.<sup>37,38</sup> The addition of 1,500 to 1,700 mg of metformin (Glucophage) daily may increase ovulation and pregnancy rates, but it does not significantly improve live birth rates over clomiphene alone.<sup>38,39</sup>

Family physicians may choose to attempt ovulation induction in anovulatory women (WHO group II) with clomiphene. Ovulation induction agents increase the risk of multiple pregnancy, ovarian hyperstimulation syndrome, and thrombosis, and they may increase the risk of ovarian cancer in women who remain nulliparous.<sup>40</sup> Patients using these agents should be counseled about these risks. The initial dosage of clomiphene is 50 mg daily for five days starting on day 3 to 5 of the menstrual cycle. This should be followed by documentation of ovulation via serum progesterone. If this is unsuccessful, the dosage may be increased to 100 mg

### BEST PRACTICES IN GYNECOLOGY: RECOMMENDATIONS FROM THE CHOOSING WISELY CAMPAIGN

<i>Recommendation</i>	<i>Sponsoring organization</i>
Do not perform immunological testing as part of the routine infertility evaluation.	American Society for Reproductive Medicine
Do not routinely order thrombophilia testing on patients undergoing a routine infertility evaluation.	American Society for Reproductive Medicine

*Source: For more information on the Choosing Wisely Campaign, see <http://www.choosingwisely.org>. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see <http://www.aafp.org/afp/recommendations/search.htm>.*


daily. Patients who do not achieve ovulation after three to six cycles should be referred to an infertility specialist for further treatment. Couples who do not conceive after treatment for six cycles with documented ovulation should also consider referral to an infertility specialist.<sup>41</sup>

### Treatment of Unexplained Infertility

Couples who have no identified cause of infertility should be counseled on timing of intercourse for the most fertile period (i.e., the six days preceding ovulation).<sup>42</sup> Urinary luteinizing hormone kits indicate the midcycle luteinizing hormone surge that precedes ovulation by one to two days. These may be purchased over the counter and allow couples to predict the most fertile days in the cycle.<sup>6</sup> Accuracy may be improved by use on midday or evening urine specimens, which correlate better with the peak in serum luteinizing hormone levels.<sup>43</sup> Other low-cost methods of monitoring for ovulation, although less effective, include basal body temperature measurements and cervical mucus changes.<sup>42</sup> However, none of these methods has been proven to increase pregnancy rates when used to predict timing of intercourse. Additionally, there is concern that the stress of a strict schedule for intercourse may lead to reduced frequency of intercourse.<sup>44</sup> Therefore, a simple recommendation is for vaginal intercourse every two to three days to optimize the chance of pregnancy.<sup>8</sup>

Patients should be counseled that 50% of couples who have not conceived in the first year of trying will conceive in the second year.<sup>8</sup> Couples with unexplained infertility may want to consider another year of intercourse before moving to more costly and invasive therapies, such as assisted reproductive technology.<sup>8</sup> Intrauterine insemination and ovulation induction do not result in increased pregnancy rates in women with unexplained infertility.<sup>8,45</sup>





**Figure 1.** Algorithm for infertility evaluation. (ART = assisted reproductive technology.)

Figure 1 provides an algorithmic approach to the evaluation of infertility.

**Lifestyle Factors**

All couples should be counseled to abstain from tobacco use, limit alcohol consumption, and aim for a body mass index less than 30 kg per m<sup>2</sup> to improve their chances of natural conception or using assisted reproductive technology.<sup>8,46</sup> Obesity impairs fertility and the response to fertility treatments, including in vitro fertilization; therefore, it is advisable to counsel patients who are obese to lose weight before conception or infertility treatments.<sup>8</sup> Involvement in group counseling and exercise is more effective than weight loss advice alone.<sup>8</sup> Counseling on lifestyle modifications is reasonable because exposures to tobacco and alcohol are associated with lower rates of fertility.<sup>47</sup> Motivational interviewing techniques for modifiable risk factors, such as obesity, tobacco, illicit drugs, and alcohol, can decrease the targeted risk factor.<sup>48</sup> However,

there is no firm evidence that preconception counseling leads to increased live birth rates, in part because no studies on this topic have been performed.<sup>10</sup>

**Data Sources:** A PubMed search was completed using the key terms infertility, subfertility, treatment, etiology, and diagnosis. It was broken down into male and female categories. The search included meta-analyses, randomized controlled trials, clinical trials, and systematic reviews. Limits were placed on language and human race as well. Also searched were the Cochrane database, the National Guideline Clearinghouse database, Dynamed, and Essential Evidence Plus. Search dates: January 6, 2014; January 28, 2014; February 5, 2014; and November 18, 2014.

The views expressed in this material are those of the authors, and do not reflect the official policy or position of the U.S. Government, the Department of Defense, or the Department of the Air Force.

**The Authors**

TAMMY J. LINDSAY, MD, FAAFP, is the chief of medical staff at Scott Air Force Base, Ill., and a clinical associate professor at Saint Louis University Family Medicine Residency in Belleville, Ill.

KIRSTEN R. VITRIKAS, MD, FAAFP, is the program director at David Grant Medical Center Family Medicine Residency at Travis Air Force Base, Calif. She is also an assistant professor at the Uniformed Services University of the Health Sciences Department of Community and Family Medicine in Bethesda, Md.

Address correspondence to Tammy J. Lindsay, MD, FAAFP, Saint Louis University Family Medicine Residency, 180 S. 3rd St., Ste. 400, Belleville, IL 62220. Reprints are not available from the authors.

**REFERENCES**

- Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United States, 1982-2010: data from the National Survey of Family Growth. *Natl Health Stat Rep.* 2013;(67):1-18.
- Chandra A, Copen CE, Stephen EH. Infertility service use in the United States: data from the National Survey of Family Growth, 1982-2010. *Natl Health Stat Report.* 2014;(73):1-21.
- Bushnik T, Cook JL, Yuzpe AA, Tough S, Collins J. Estimating the prevalence of infertility in Canada [published correction appears in *Hum Reprod.* 2013;28(4):1151]. *Hum Reprod.* 2012;27(3):738-746.
- Oakley L, Doyle P, Maconochie N. Lifetime prevalence of infertility and infertility treatment in the UK: results from a population-based survey of reproduction. *Hum Reprod.* 2008;23(2):447-450.
- Gutmacher AF. Factors effecting normal expectancy of conception. *J Am Med Assoc.* 1956;161(9):855-860.
- Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. *Fertil Steril.* 2012;98(2):302-307.
- Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). *Hum Reprod.* 1991;6(6):811-816.
- National Collaborating Centre for Women's and Children's Health. Fertility: assessment and treatment for people with fertility problems.

- London, United Kingdom: National Institute for Health and Clinical Excellence (NICE); February 2013:1-63. (Clinical guideline no. 156).
9. Hinton L, Kurinczuk JJ, Ziebland S. Reassured or fobbed off? Perspectives on infertility consultations in primary care: a qualitative study. *Br J Gen Pract.* 2012;62(599):e438-e445.
  10. Anderson K, Norman RJ, Middleton P. Preconception lifestyle advice for people with subfertility. *Cochrane Database Syst Rev.* 2010;(4):CD008189.
  11. Hull MG, North K, Taylor H, Farrow A, Ford WC. Delayed conception and active and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood Study Team. *Fertil Steril.* 2000;74(4):725-733.
  12. Hijlund NH, Storgaard L, Ernst E, Bonde JP, Olsen J. The relation between daily activities and scrotal temperature. *Reprod Toxicol.* 2002;16(3):209-214.
  13. de La Rochebrochard E, Thonneau P. Paternal age > or = 40 years: an important risk factor for infertility. *Am J Obstet Gynecol.* 2003;189(4):901-905.
  14. Hassan MA, Killick SR. Effect of male age on fertility: evidence for the decline in male fertility with increasing age. *Fertil Steril.* 2003;79(suppl 3):1520-1527.
  15. Sermondade N, Faure C, Fezeu L, Lévy R, Czernichow S; Obesity-Fertility Collaborative Group. Obesity and increased risk for oligozoospermia and azoospermia. *Arch Intern Med.* 2012;172(5):440-442.
  16. Povey AC, Clyma JA, McNamee R, et al.; Participating Centres of Chaps-UK. Modifiable and non-modifiable risk factors for poor semen quality: a case-referent study. *Hum Reprod.* 2012;27(9):2799-2806.
  17. Gracia CR, Sammel MD, Coutifaris C, Guzick DS, Barnhart KT. Occupational exposures and male infertility. *Am J Epidemiol.* 2005;162(8):729-733.
  18. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. *Hum Reprod Update.* 2010;16(3):231-245.
  19. American Urological Association Education and Research, Inc. The evaluation of the azoospermic male: AUA best practice statement. Linticum, Md.: American Urological Association, Inc.; 2010.
  20. Hofherr SE, Wiktor AE, Kipp BR, Dawson DB, Van Dyke DL. Clinical diagnostic testing for the cytogenetic and molecular causes of male infertility: the Mayo Clinic experience. *J Assist Reprod Genet.* 2011;28(11):1091-1098.
  21. Kamel RM. Management of the infertile couple: an evidence-based protocol. *Reprod Biol Endocrinol.* 2010;8:21.
  22. Oei SG, Helmerhorst FM, Bloemenkamp KW, Hollants FA, Meerpoel DE, Keirse MJ. Effectiveness of the postcoital test: randomised controlled trial. *BMJ.* 1998;317(7157):502-505.
  23. Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ. *WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple.* New York, NY: Cambridge University Press; 1993.
  24. Nelson LM. Clinical practice. Primary ovarian insufficiency. *N Engl J Med.* 2009;360(6):606-614.
  25. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. *Hum Reprod Update.* 2006;12(6):685-718.
  26. Opsahl MS, Miller B, Klein TA. The predictive value of hysterosalpingography for tubal and peritoneal infertility factors. *Fertil Steril.* 1993;60(3):444-448.
  27. Luttjeboer F, Harada T, Hughes E, Johnson N, Lilford R, Mol BW. Tubal flushing for subfertility. *Cochrane Database Syst Rev.* 2007;(3):CD003718.
  28. Coutifaris C, Myers ER, Guzick DS, et al.; NICHD National Cooperative Reproductive Medicine Network. Histological dating of timed endometrial biopsy tissue is not related to fertility status. *Fertil Steril.* 2004;82(5):1264-1272.
  29. Jungwirth A, Giwercman A, Tournaye H, et al. European Association of Urology guidelines on male infertility: the 2012 update. *Eur Urol.* 2012;62(2):324-332.
  30. Baazeem A, Belzile E, Ciampi A, et al. Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. *Eur Urol.* 2011;60(4):796-808.
  31. Kroese AC, de Lange NM, Collins J, Evers JL. Surgery or embolization for varicoceles in subfertile men. *Cochrane Database Syst Rev.* 2012;(10):CD000479.
  32. Evers JL, Collins JA. Assessment of efficacy of varicocele repair for male subfertility: a systematic review. *Lancet.* 2003;361(9372):1849-1852.
  33. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. *Cochrane Database Syst Rev.* 2013;(8):CD005071.
  34. Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. *Cochrane Database Syst Rev.* 2011;(1):CD007411.
  35. Bendsdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-uterine insemination for male subfertility. *Cochrane Database Syst Rev.* 2007;(4):CD000360.
  36. Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. *Cochrane Database Syst Rev.* 2012;(9):CD001838.
  37. Vause TD, Cheung AP, Sierra S, et al.; Society of Obstetricians and Gynecologists of Canada. Ovulation induction in polycystic ovary syndrome [published corrections appear in *J Obstet Gynaecol Can.* 2010;32(11):1027, and *J Obstet Gynaecol Can.* 2011;33(1):12]. *J Obstet Gynaecol Can.* 2010;32(5):495-502.
  38. Sun X, Zhang D, Zhang W. Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. *Arch Gynecol Obstet.* 2013;288(2):423-430.
  39. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Cochrane Database Syst Rev.* 2012;(5):CD003053.
  40. Trabert B, Lamb EJ, Scoccia B, et al. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. *Fertil Steril.* 2013;100(6):1660-1666.
  41. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. *Fertil Steril.* 2013;100(2):341-348.
  42. Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility: a committee opinion. *Fertil Steril.* 2013;100(3):631-637.
  43. Luciano AA, Peluso J, Koch EI, Maier D, Kuslis S, Davison E. Temporal relationship and reliability of the clinical, hormonal, and ultrasonographic indices of ovulation in infertile women. *Obstet Gynecol.* 1990;75(3 pt 1):412-416.
  44. Andrews FM, Abbey A, Halman LJ. Is fertility-problem stress different? The dynamics of stress in fertile and infertile couples. *Fertil Steril.* 1992;57(6):1247-1253.
  45. Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. *Cochrane Database Syst Rev.* 2010;(1):CD000057.
  46. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod.* 1998;13(6):1502-1505.
  47. Weinberg CR, Wilcox AJ, Baird DD. Reduced fecundability in women with prenatal exposure to cigarette smoking. *Am J Epidemiol.* 1989;129(5):1072-1078.
  48. Homan G, Litt J, Norman RJ. The FAST study: fertility assessment and advice targeting lifestyle choices and behaviours: a pilot study. *Hum Reprod.* 2012;27(8):2396-2404.